Shares of hVIVO plc (LON:HVO - Get Free Report) fell 9.1% on Wednesday . The company traded as low as GBX 18 ($0.22) and last traded at GBX 18.54 ($0.23). 6,675,894 shares traded hands during mid-day trading, an increase of 126% from the average session volume of 2,957,933 shares. The stock had previously closed at GBX 20.40 ($0.25).
hVIVO Stock Performance
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock's fifty day moving average is GBX 19.78 and its two-hundred day moving average is GBX 25.40. The firm has a market cap of £127.91 million, a price-to-earnings ratio of 626.67 and a beta of 0.97.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
